![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
May 1, 2024
EA2212 is a randomized phase 2 study assessing if chemotherapy plus immunotherapy is superior to immunotherapy alone for patients with operable MSI-H/dMMR gastric and/or gastroesophageal junction cancer
February 9, 2024
Colleagues at ThedaCare and the Metro-Minnesota Community Oncology Research Consortium share their perspectives on facilitating just-in-time access to NCTN therapeutic trials
December 19, 2023
The Fall 2023 Group Meeting was notable for a prominent increase in attention to diversity, equity, and inclusion
December 19, 2023
Elevating the role of APPs as partners in the clinic will help to reinforce the important role clinical trials play in cancer care and strengthen accrual efforts
December 19, 2023
In an annual evaluation, 46 member networks and programs met rigorous standards established by ECOG-ACRIN to indicate exemplary cancer research
October 19, 2023
Following the recent Nature Medicine publication of lessons from the NCI-MATCH trial, two new podcasts discuss the pitfalls and promises of precision oncology—and opportunities to guide the field as it moves forward
October 19, 2023
Matthias Weiss, MD, of ThedaCare, and Kim Reiss, MD, of the University of Pennsylvania, discuss current trends in precision oncology
June 30, 2023
The Group is recognizing Dr. Forde as an exceptional physician-scientist who is making significant research contributions as a translational thoracic cancer investigator
June 30, 2023
The Group is recognizing Dr. Forastiere for her sustained commitment to developing women’s careers in cancer medicine and advancing women investigators in ECOG-ACRIN
June 30, 2023
At a recent meeting, ECOG-ACRIN leaders and members celebrated the conclusion of enrollment to the landmark NCI-MATCH clinical trial
December 20, 2022
Some of the most memorable moments of the 10th Anniversary General Session featured three individuals who have been key participants and collaborators in ECOG-ACRIN’s research over the years
December 20, 2022
In an annual evaluation, 36 member networks and programs met rigorous standards established by ECOG-ACRIN to indicate exemplary cancer research